| Test code: | 119 |
| Type of disorder: | Movement Disorders |
| Disease(s) tested for: | Friedreich's Ataxia |
| Genes Included: | FXN, |
| Profiles that contain this test: | Ataxia, Complete Recessive Evaluation Ataxia, Comprehensive Evaluation Ataxia, Friedreich (FXN) Evaluation |
| Informed Consent Required: | This test requires physician attestation that patient consent has been received |
| Patents: | 6,150,091 |
| Clinical Significance: | Detects GAA triplet repeat expansion in the Frataxin gene |
| Methodology: | Repeat Expansion Detection by PCR, Long Read Sequencing |
| Reference Range: | Normal: <=33 GAA trinucleotide repeats |
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
| CPT: | 81284(1) |
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
| Specimen Type: | Whole blood |
| Specimen Stability: | |
| Instructions: | Higher blood volumes ensure adequate DNA quantity, which varies with WBC, specimen condition, and need for confirmatory testing. Patients, 0-3 years have higher WBC, yielding more DNA per mL of blood. |
| Transport Temperature: | Room temperature |
| Set-up/Analytic Time: | 14-28 days |
Home